Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,780 | 1,764 | 13.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CROSSJECT Aktie jetzt für 0€ handeln | |||||
Mi | CROSSJECT advances on the development of ZEPIZURE Junior, its solution for epilepsy crises in children | 63 | GlobeNewswire (Europe) | Press release CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children Announces the effective calibration of ZENEO® for the use of ZEPIZURE® in the... ► Artikel lesen | |
04.06. | CROSSJECT: Launch of a capital increase with preferential subscription rights for nearly 5 million euros | 1 | GlobeNewswire (USA) | ||
03.06. | Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 | 45 | GlobeNewswire (Europe) | Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265... ► Artikel lesen | |
27.05. | CROSSJECT implements new manufacturing module to scale-up the ZENEO Factory 's versatility and capacity in anticipation of full product pipeline deployment | 3 | GlobeNewswire (USA) | ||
20.05. | CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval | 2 | GlobeNewswire (USA) | ||
15.05. | CROSSJECT's ZENEO needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors | 88 | GlobeNewswire (Europe) | Press Release CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors... ► Artikel lesen | |
07.05. | CROSSJECT provides updates on the EUA filing of ZEPIZURE | 2 | GlobeNewswire (USA) | ||
27.03. | CROSSJECT reports financial results for 2024 | 148 | GlobeNewswire (Europe) | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | 172 | GlobeNewswire (Europe) | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
18.03. | CROSSJECT achieves key ZEPIZURE manufacturing batch stability milestones | 1 | GlobeNewswire (USA) | ||
12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 167 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 136 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 152 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen | |
23.09.24 | Crossject reports financial results and business highlights for the first six months of 2024 | 276 | GlobeNewswire (Europe) | Available cash €5.95 million, up from €2.3 million on December 31, 2023Reports stable investments in R&D and consolidation of operating income from BARDACompany on track to successfully file for the... ► Artikel lesen | |
19.08.24 | Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE Epilepsy Rescue Treatment | 303 | GlobeNewswire (Europe) | Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment Experienced executive to lead preparations... ► Artikel lesen | |
18.07.24 | Crossject achieves key ZEPIZURE manufacturing milestone | 207 | GlobeNewswire (Europe) | Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is... ► Artikel lesen | |
10.07.24 | Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO Epinephrine | 218 | GlobeNewswire (Europe) | Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French companies... ► Artikel lesen | |
26.06.24 | Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study | 282 | GlobeNewswire (Europe) | Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 44,000 | -0,54 % | Kurs der Fresenius SE & Co. KGaA-Aktie verharrt auf Vortags-Niveau (43,90 €) | Im deutschen Wertpapierhandel ist die Fresenius SE & Co. KGaA-Aktie zur Stunde unauffällig. Das Papier notiert gegenwärtig bei 43,90 Euro. Wenig getan hat sich heute bislang beim Kurs von Fresenius+Co... ► Artikel lesen | |
INTUITIVE SURGICAL | 442,75 | -0,12 % | Intuitive Surgical unter Druck: Ist der Burggraben in Gefahr? | Das US-Unternehmen Intuitive Surgical ist der unangefochtene Marktführer in der Roboter-assistierten Chirurgie. In immer mehr OP-Sälen sind die präzisen Hightech-Roboter nicht mehr wegzudenken. Doch... ► Artikel lesen | |
HIMS & HERS HEALTH | 47,910 | -0,31 % | Massive Veränderung voraus? Hims & Hers Health, Novartis, PanGenomic Health, Pfizer | Mit einem Paukenschlag wartete Anfang der Woche der US-Gesundheitsminister Robert Kennedy auf. Der Kritiker an dem massiven Anstieg der Impfhäufigkeit in den letzten 40 Jahren in den USA gab bekannt... ► Artikel lesen | |
SERNOVA BIOTHERAPEUTICS | 0,101 | -0,98 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
FAMICORD | 4,200 | +1,45 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
GERATHERM MEDICAL | 3,210 | -1,83 % | Geratherm Medical AG: GJ24 war herausfordernd, vorsichtige Prognose für GJ25; mwb research bekräftigt KAUFEN | Die Ergebnisse von Geratherm für das Geschäftsjahr 2024 zeigten einen Umsatzrückgang von 33% auf 14,0?Mio.?EUR, was in erster Linie auf deutliche Rückgänge in den Bereichen Healthcare Diagnostics und... ► Artikel lesen | |
ALIGN TECHNOLOGY | 156,00 | +1,27 % | Align Technology-Aktie heute am Aktienmarkt kaum gefragt: Kurs fällt (154,1425 €) | Die Align Technology-Aktie notiert heute ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 174,85 US-Dollar. Das Wertpapier von Align Technology verzeichnet aktuell einen Abschlag von 4,24... ► Artikel lesen | |
NUGEN MEDICAL DEVICES | 0,040 | -1,00 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
PLUS THERAPEUTICS | 0,314 | -10,05 % | Plus Therapeutics Inc.: Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | Company continues to progress both REYOBIQ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness HOUSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
CARDINAL HEALTH | 140,45 | +0,50 % | Aktienmarkt: Aktie von Cardinal Health tritt auf der Stelle (134,7333 €) | Die Wertschätzung für die Aktie von Cardinal Health hat sich an der Börse am Montag kaum geändert. Das Wertpapier notiert gegenwärtig bei 153,98 US-Dollar. Kaum verändert im Vergleich zu der letzten... ► Artikel lesen | |
RESMED | 215,50 | -0,23 % | Dividendenbekanntmachungen (12.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADT INC US00090Q1031 0,055 USD 0,0478 EUR ALAMOS GOLD INC CA0115321089 0,0342 CAD 0,0218 EUR ALIBABA GROUP HOLDING LTD ADR US01609W1027 1... ► Artikel lesen | |
DAVITA | 117,35 | -0,42 % | DAVITA INC. - 8-K, Current Report | ||
SIEMENS HEALTHINEERS | 45,650 | -1,64 % | Healthineers Exit in 2026?: Outperform! Deshalb bleibt Siemens für diesen Analysten ein klarer Kauf | © Foto: Joko - JokoEgal ob Automatisierung, Elektrifizierung oder Industrie-Software. Der Traditionskonzern Siemens mischt bei sämtlichen Zukunftstrends mit. Auch für Anleger und Analysten bleibt die... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 49,880 | +0,02 % | EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Fresenius Medical Care AG
Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]... ► Artikel lesen | |
GERRESHEIMER | 46,780 | -1,97 % | Abnehmspritzen-Profiteur: Gerresheimer: Übernahmespekulationen könnten für den Rebound sorgen | © Foto: Revierfoto - RevierfotoBei den deutschen Nebenwerten sorgte der Verpackungsspezialist Gerresheimer in dieser Woche für eine böse Überraschung. Analysten ließen die Aktien anschließend reihenweise... ► Artikel lesen |